α2-Adrenergic receptors are not required for central anti-hypertensive action of moxonidine in mice

Brain Research

Volumn 862, Issue 1-2, 2000, Pages 26-35

  Tolentino Silva, F P ^a   Haxhiu, M A ^b   Waldbaum, Simon ^b   Dreshaj, I A ^b   Ernsberger, P ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

(2a) Adrenergic mice; Arterial blood pressure; Cardiovascular regulation; Catecholamine receptors; Hypertension; I1 imidazoline receptors; Moxonidine; Neurotransmitters, modulators, transporters, and receptors; Rostral ventrolateral medulla; Wild type mice

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 1H 3 BENZAZEPINE; ALPHA 2 ADRENERGIC RECEPTOR; EFAROXAN; IMIDAZOLINE I1 RECEPTOR; IMIDAZOLINE I2 RECEPTOR; MOXONIDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR HYPOTHALAMUS; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; ARTICLE; BRAIN REGION; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HEART RATE; HYPERTENSION; MEAN ARTERIAL PRESSURE; MEDULLA OBLONGATA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADRENERGIC ALPHA-ANTAGONISTS; AMYGDALA; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZOFURANS; BINDING, COMPETITIVE; BLOOD PRESSURE; BRAIN CHEMISTRY; GLUTAMIC ACID; HEART RATE; HYPERTENSION; IMIDAZOLES; INJECTIONS, INTRAVENOUS; MEDULLA OBLONGATA; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MICROINJECTIONS; PONS; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DRUG;

EID: 0034678538     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(00)02089-8     Document Type: Article

References (30)

1. Altman J.D., Trendelenburg A.U., MacMillan L., Bernstein D., Limbird L., Starke K., Kobilka B.K., Hein L. Abnormal regulation of the sympathetic nervous system in α2A-adrenergic receptor knockout mice. Mol. Pharmacol. 56:1999;154-161.
2. Arango V., Ernsberger P., Reis D.J., Mann J.J. Demonstration of high- and low-affinity β-adrenergic receptors in slide-mounted sections of rat and human brain. Brain Res. 516:1990;113-121.
3. Bock C., Niederhoffer N., Szabo B. Analysis of the receptor involved in the central hypotensive effect of rilmenidine and moxonidine. Naunyn Schmiedeberg's Arch. Pharmacol. 359:1999;262-271.
4. Bousquet P., Feldman J., Bloch R., Schwartz J. Central cardiovascular effects of α-adrenergic drugs: Differences between catecholamines and imidazolines. J. Pharmacol. Exp. Ther. 230:1984;232-236.
5. Bousquet P., Guertzenstein P.G. Localization of the central cardiovascular action of clonidine. Br. J. Pharmacol. 49:1973;573-579.
6. 2-adrenergic receptors in the antihypertensive responses evoked by central administration of clonidine analogs in conscious spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 273:1995;1162-1171.
7. Chan C.K.S., Sannajust F., Head G.A. Role of imidazoline receptors in the cardiovascular actions of moxonidine, rilmenidine and clonidine in conscious rabbits. J. Pharmacol. Exp. Ther. 276:1996;411-420.
8. 1-imidazoline receptor: From binding site to therapeutic target in cardiovascular disease. J. Hypertens. 15:(Suppl. 1):1997;S9-S23.
9. 1-imidazoline-binding site is a functional receptor mediating vasodepression via the ventral medulla. Am. J. Physiol. 273:1997;R1572-R1579.
10. 2-adrenoceptors in the ventrolateral medulla. Eur. J. Pharmacol. 134:1987;1-13.
11. 1-imidazoline sites. Ann. NY Acad. Sci. 763:1995;163-168.
12. 1-imidazoline agonist moxonidine administered into the rostral ventrolateral medulla. J. Cardiovasc. Pharmacol. 20:(Suppl. 4):1992;S11-S15.
13. 1-imidazoline receptors in the rostral ventrolateral medulla. J. Cardiovasc. Pharmacol. 24:(Suppl. 1):1994;S1-S8.
14. Hein L., Limbird L.E., Eglen R.M., Kobilka B.K. Gene substitution/knockout to delineate the role of alpha 2- adrenoceptor subtypes in mediating central effects of catecholamines and imidazolines. Ann. NY Acad. Sci. 881:1999;265-271.
15. 2-adrenoceptor blockade by SKF 86466: In vitro characterization of receptor selectivity. J. Pharmacol. Exp. Ther. 236:1986;90-96.
16. 2-adrenoceptors. Br. J. Pharmacol. 110:1993;1635-1639.
17. 2α-adrenergic receptor subtype. Science. 273:1996;801-803.
18. Makaritsis K.P., Johns C., Gavras I., Altman J.D., Handy D.E., Bresnahan M.R., Gavras H. Sympathoinhibitory function of the α(2A)-adrenergic receptor subtype. Hypertension. 34:1999;403-407.
19. Nicholas A.P., Pieribone V., Hökfelt T. Distributions of mRNAs for α2 adrenergic receptor subtypes in rat brain: An in situ hybridization study. J. Comp. Neurol. 328:1993;575-594.
20. Nichols A.J., Ruffolo R.R. Jr. Functions mediated by α-adrenoceptors. Prog. Basic Clin. Pharmacol. 8:1991;115-179.
21. Scheinin M., Lomasney J.W., Hayden-Hixson D.M., Schambra U.B., Caron M.G., Lefkowitz R.J., Fremeau R.T. Jr. Distribution of a2-adrenergic receptor subtype gene expression in rat brain. Mol. Brain Res. 21:1994;133-149.
22. 1-imidazoline receptors in PC12 cells and rostral ventrolateral medulla. Brain Res. 749:1997;335-339.
23. Sun M.-K. Central neural organization and control of sympathetic nervous system in mammals. Prog. Neurobiol. 47:1995;157-234.
24. 1 imidazoline receptors in the sympathoinhibition produced by intracisternally administered rilmenidine and moxonidine. Arzneimittel-Forschung. Drug Res. 47:1997;1009-1015.
25. 2-agonist binding sites in the rat and human central nervous system: Analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents. Brain Res. Rev. 7:1984;69-101.
26. 2-adrenoceptors in the cardiovascular effects of moxonidine. Eur. J. Pharmacol. 282:1995;19-28.
27. Van Zwieten P.A., Thoolen M.J.M., Timmermans P.B.M.W.M. The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine. Hypertension. 6:(Suppl. 11):1984;s28-s33.
28. Zhu Q.M., Lesnick J.D., Jasper J.R., MacLennan S.J., Dillon M.P., Eglen R.M., Blue D.R. Jr. Alpha 2A-adrenoceptors, not I1-imidazoline receptors, mediate the hypotensive effects of rilmenidine and moxonidine in conscious mice. In vivo and in vitro studies. Ann. NY Acad. Sci. 881:1999;287-289.
29. Zhu Q.M., Lesnick J.D., Jasper J.R., MacLennan S.J., Dillon M.P., Eglen R.M., Blue D.R. Jr. Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br. J. Pharmacol. 126:1999;1522-1530.
30. 1-imidazoline receptor agonist. J. Cardiovasc. Pharmacol. 27:(Suppl. 3):1996;S26-S37.